A new prognostic marker in small cell lung cancer: red cell distribution width ratio of hemoglobin

Aim: The ratio of hemoglobin (Hb) to red cell distribution width (RDW) (HRR) has been defined as an effective prognostic factor in various cancer types. The aim of this study is to investigate the prognostic role of HRR value in small cell lung cancer (SCLC). Material and Method: A total of 1039 patients diagnosed with SCLC between 2010-2021 were included in the study. After exclusion of 199 patients without positron emission tomography-computerized tomography (PET-CT), age, gender, additional disease histories, smoking history, pathological stages, survival status, disease progression times, treatments applied, first hemoglobin obtained after diagnosis, red cell distribution width and ratios, and other laboratory parameters of 840 patients were recorded. The log-rank test and the Cox proportional hazards model were used to identify predictors of mortality. Results: A total of 840 patients were included in the study. The median overall survival (OS) and the progression-free survival (PS) times of the patients were 9 months, and 7 months, respectively. The cut-off value for HRR was determined 0.580 (sensitivity 78.73%, specificity 37.88%). In this study, each one-unit increase in HRR reduces death and survival by 1.6 times detected, and it was revealed that HRR had a statistically significant effect on OS and PS. When the patients were divided into two as limited and extensive disease, there was a statistically significant difference between the groups in terms of OS (12-6 months) and PS (10-6 months), but no significant difference was found in terms of HRR between these two groups. Conclusion: HRR is an easily accessible, inexpensive parameter that can be used as a prognostic marker in patients with SCLC.

Keywords:

HRR, SCLC survival, prognosis,

PDF

___

Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: Beyond traditional treatment approaches. J Thorac Oncol 2013; 8: 587–98.
Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Aamdal S. Second‐line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP‐regimen) or cyclophosphamide, epirubicin, and vincristin (CEV‐regimen). Lung Cancer 2005; 48: 251–61.
Zhou T, Zhao Y, Zhao S. Comparison of the prognostic value of systemic inflammation response markers in small cell lung cancer patients. J Cancer 2019; 10: 1685–92.
Kang EJ, Lee SY, Kim HJ. Prognostic factors and skeletal‐related events in patients with small cell lung cancer with bone metastases at the time of diagnosis. Oncology 2016; 90: 103-11.
Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: Results from a randomised multicenter study with minimum 5 year follow‐up. Lung Cancer 2003; 39: 303–13.
Zalcman G, Tredaniel J, Schlichtholz B. Prognostic significance of serum p53 antibodies in patients with limited‐stage small cell lung cancer. Int J Cancer 2000; 89: 81–6.
Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-21.
Riedl J, Posch F, Königsbrügge O, et al. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality. PLoS ONE 2014; 9: 111440.
Ellingsen TS, Lappegård J, Skjelbakken T, Brækkan SK, Hansen JB. Impact of red cell distribution width on future risk of cancer and all-cause mortality among cancer patients-The Tromsø Study. Haematologica 2015; 100: 387–9.
Ichinose J, Murakawa T, Kawashima M. Prognostic significance of red cell distribution width in elderly patients undergoing resection for non‐small cell lung cancer. J Thorac Dis 2016; 8: 3658–66.
Seretis C, Seretis F, Lagoudianakis E, Gemenetzis G. Salemis NS. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study. J Clin Med Res 2013; 5: 121–6.
Chen GP, Huang Y, Yang X, Feng JF. A nomogram to predict prognostic value of red cell distribution width in patients with esophageal cancer. Mediators Inflamm 2015; 2015: 854670.
Wang FM, Xu G, Zhang Y, Ma LL. Red cell distribution width is associated with presence, stage, and grade in patients with renal cell carcinoma. Dis Markers 2014; 2014: 860419.
Petrella F, Casiraghi M, Radice D, et al. Prognostic value of the hemoglobin/red cell distribution width ratio in resected lung adenocarcinoma. Cancers 2021; 13: 710.
Wu F, Yang S, Tang X, Liu W, Chen H, Gao H. Prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio in small cell lung cancer: a retrospective analysis. Thorac Cancer 2020; 11: 888–97.
Goldstraw P, Chansky K, Crowley J. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51.
Sun P, Zhang F, Chen C. The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China. Oncotarget 2016; 7: 42650–60.
Tham T, Olson C, Wotman M. Evaluation of the prognostic utility of the hemoglobin‐to‐red cell distribution width ratio in head and neck cancer. Eur Arch Otorhinolaryngol 2018; 275: 2869–78.
Yakup B, Bediz K, Fatih G. A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width. Int J Clin Oncol 2019; 24: 798-806.
Wu F, Yang S, Tang X, Liu W, Chen H, Gao H. Prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio in small cell lung cancer: a retrospective analysis. Thorac Cancer 2020; 11: 888–97.
Petrella F, Casiraghi M, Radice D, et al. Prognostic value of the hemoglobin/red cell distribution width ratio in resected lung adenocarcinoma. Cancers 2021; 13: 710.
Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic significance of total lymphocyte count, neutrophil‐to‐lymphocyte ratio, and platelet‐to‐lymphocyte ratio in limited‐stage small‐cell lung cancer. Clin Lung Cancer 2019; 20: 117–23.